Immuneering Corporation — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2022. Immuneering is a clinical-stage biotechnology company developing therapies for RAS-mutant and other MAPK-pathway-driven solid tumors. It has no approved products and is transitioning away from computational biology services to focus on its drug pipeline.
Financial results
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $38,380 | $482,130 | $316,497 | $1,890,370 |
| Gross profit | $19,037 | $263,042 | $158,375 | $943,518 |
| Research and development | $9.36 million | $6.21 million | $26.40 million | $18.59 million |
| General and administrative | $3.84 million | $2.60 million | $11.50 million | $5.12 million |
| Net loss | $12.84 million | $8.53 million | $37.27 million | $22.75 million |
| Net loss per share, basic and diluted | $0.49 | $0.47 | $1.41 | $2.41 |
- Q3 revenue fell 92.1%; nine-month revenue fell 83.3%, reflecting fewer and reduced-scope service contracts. The company completed its last remaining computational biology services contract in September 2022 and does not anticipate new service contracts.
- Operating expenses rose as the company expanded internal research, staffing and facilities and incurred public-company costs. For the first nine months, R&D increased 42.0% and G&A increased 124.5% year over year. The resulting net loss increased 63.8%.
- Cash and cash equivalents were $76.4 million at September 30, 2022; marketable securities were $40.8 million, for combined cash and securities of approximately $117.2 million, down from approximately $150.2 million at December 31, 2021. Total assets were $133.7 million and stockholders’ equity was $121.9 million.
- Operating activities used $32.4 million of cash in the nine-month period. Investing activities provided $33.7 million, mainly from maturities of marketable securities; financing activities provided $0.2 million. The reported $1.5 million increase in cash therefore does not reflect cash generated by operations.
- The filing reports no borrowings or debt balance. Total lease liabilities were $4.85 million, including $0.31 million current. Total liabilities were $11.8 million.
Material developments and outlook
- The FDA allowed the Phase 1/2a trial of lead candidate IMM-1-104 to proceed on September 30, 2022. The company was recruiting and planned to dose the first patient in Q4 2022. The trial is intended to assess safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity.
- Management planned to submit an IND for IMM-6-415 in Q4 2023 and anticipated at least one additional oncology IND in 2024. IMM-6-415 remained in IND-enabling studies; other oncology and neuroscience programs were earlier-stage.
- Management estimated existing cash and marketable securities would fund operating expenses and capital expenditures into Q3 2024. This estimate depends on assumptions and could prove too optimistic; additional capital will be needed thereafter unless costs, funding or plans change.
- In August 2022, the company established a $50 million at-the-market equity program with Piper Sandler. No shares were sold under it through September 30, 2022. Any future issuance could dilute existing stockholders.
- The company expects losses and R&D and G&A expenses to increase as it advances clinical development. It was also winding down external biosample-storage services acquired with BioArkive, with completion expected by the end of 2022.
Risks, contingencies and unusual items
- Immuneering has a limited drug-development history, no approved products and recurring losses. It depends on additional capital and may have to delay, reduce or terminate programs if funding is unavailable on acceptable terms.
- Clinical, regulatory, manufacturing and enrollment outcomes are uncertain. The filing highlights risks from adverse events, trial delays, reliance on third-party CROs and manufacturers, competition, intellectual-property protection and possible COVID-19-related disruption.
- The company reported no material legal proceedings and no material off-balance-sheet arrangements. It identified no goodwill impairment trigger in Q3.
- BioArkive acquisition-related intangible amortization was $7,317 for Q3 and $22,737 for the nine months. The company also terminated a BioArkive-associated lease and sublease early in August after the building was sold; the remaining right-of-use asset and lease liability were written off.
- Disclosure controls and procedures were assessed as effective at the reasonable-assurance level; no material change in internal control over financial reporting was reported for Q3.
Investor verification priorities
- Check whether IMM-1-104 began dosing in Q4 2022 as planned and review trial enrollment, safety and emerging data.
- Track actual cash burn and spending against the stated runway into Q3 2024, including whether the ATM program is used and the resulting dilution.
- Verify the timing and progress of the IMM-6-415 IND and the anticipated additional oncology IND.
- Monitor the wind-down of service and external biosample-storage revenue and the resulting shift in expenses toward drug development.
- Assess whether clinical execution, third-party supply, regulatory requirements or other risks materially change the company’s development plans or funding needs.